Seagen (SGEN) Stock Price, News & Analysis

Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Key Stats

• Today's Range: $228.74 to $228.74
• 50-Day Range: $228.74 to $228.74
• 52-Week Range: $123.77 to $228.96
• Volume: 86 shs
• Average Volume: 1.48 million shs
• Market Capitalization: $42.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Seagen Stock Analysis - MarketRank™

Seagen scored higher than 15% of companies evaluated by MarketBeat, and ranked 898th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Seagen.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Seagen are expected to grow in the coming year, from ($3.82) to ($1.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Seagen is -57.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Seagen has a P/B Ratio of 15.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SGEN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Seagen does not currently pay a dividend.

Dividend Growth

Seagen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 2.5 / 5
• Environmental Score: -2.86

Short Interest

There is no current short interest data available for SGEN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for SGEN on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Seagen insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.90% of the stock of Seagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.26% of the stock of Seagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SGEN Stock Analysis - Frequently Asked Questions

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The firm's quarterly revenue was up 27.1% on a year-over-year basis.

Does Seagen have any subsidiaries?

The following companies are subsidiaries of Seagen: Cascadian Therapeutics.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), Meta Platforms (META), Intel (INTC), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE) and QUALCOMM (QCOM).

Company Calendar

• Last Earnings: 11/01/2023
• Today: 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGEN
• CIK: 1060736
• Web: www.seattlegenetics.com
• Phone: (425) 527-4000
• Fax: 425-527-4001
• Employees: 3,256
• Year Founded: 1998

Profitability

• EPS (Most Recent Fiscal Year): ($4.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-610,310,000.00
• Net Margins: -32.61%
• Pretax Margin: -32.12%
• Return on Equity: -28.06%
• Return on Assets: -20.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.67
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $2.30 billion
• Price / Sales: 18.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.10 per share
• Price / Book: 15.15

Miscellaneous

• Outstanding Shares: 187,698,000
• Free Float: 139,084,000
• Market Cap: $42.93 billion
• Optionable: Optionable
• Beta: 0.32